News
Technology has also improved immunisation operations with the use of online appointment scheduling that automates ...
Biogen has been trying to build up its R&D pipeline as it faces increased competition for its biggest-selling products like Spinraza (nusinersen) for spinal muscular atrophy (SMA) and its multiple ...
The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...
Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build next-gen central nervous system drugs. | Big Biotech Biogen is venturing into ...
Dravet syndrome is a severe form of epilepsy, usually diagnosed in infancy, that is associated with developmental delays and severe seizures. It has long been recognized for its neurological symptoms, ...
A new gene replacement therapy for Dravet syndrome alleviated symptoms in mice, offering hope for more effective human treatments. Further research is needed.
" Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures ...
Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...
Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m The rare genetic epilepsy affects up to 38,000 people in the US, UK, EU and Japan Biogen and Stoke Therapeutics have ...
CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ: BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ: STOK) ...
Biogen has entered a collaboration with Stoke Therapeutics to develop and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico, and the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results